Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021
Kite’s Tecartus Receives the US FDA’s Approval as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Shots:
- The P-II ZUMA-5 trial assessing Yescarta in 146 patients aged ≥18rs. with r/r iNHL include FL, prior treated with at least 2L of systemic therapy
- Results: 94% of patients achieved a response @18mos., & 2EPs of mPFS and OS were not yet reached. In a weighted analysis, the results compared with ZUMA-5 patients vs SCHOLAR-5 patients, therapy showed superior OS & PFS over currently available treatments
- Patients achieved a response (94% vs 50%) @median follow-up of 26.2 mos., reduction in risk of disease progression (58% vs 70%), relapse or death vs current therapies in a control cohort, m-PFS & OS (12.7 & 59.8 mos.) in a control cohort, respectively
Click here to read full press release/ article | Ref: Business Wire | Image: Business Wire